Clinical Trials Logo

Filter by:
NCT ID: NCT05510843 Terminated - Clinical trials for Chronic Cold Urticaria

A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Start date: September 6, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

NCT ID: NCT05509829 Recruiting - Breast Cancer Clinical Trials

EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery

LAUREN
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Negative pressure wound therapy (NPWT) could improve surgical outcomes and reduce complications like SSI, wound dehiscence and seroma in closed surgical wounds. To date, NPWT was not evaluated in patients undergoing breast conserving surgery without direct reconstruction.Therefore, the aim of this trial is to evaluate the feasibility of NPWT after surgery and its effects on postoperative complications.

NCT ID: NCT05509777 Recruiting - Crohn's Disease Clinical Trials

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

AMAY
Start date: March 13, 2024
Phase: Phase 3
Study type: Interventional

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: - A 12-week induction period - A maintenance period from Week 12 to Week 52, and - A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.

NCT ID: NCT05509647 Completed - COVID-19 Clinical Trials

Unfractionated Heparin in COVID-19 and Non-COVID-19 Patients

Start date: January 1, 2014
Phase:
Study type: Observational

The majority of ICU patients with COVID-19 show profound activation of coagulation, potentially resulting in thromboembolic events. In the treatment of these thromboembolic events it seemed that very high dosages of unfractionated heparin were necessary to achieve therapeutic values of aPTT and anti-Xa levels. The aim of this study is to explore whether heparin dosages are higher in COVID-19 patients compared to non-COVID-19 patients, to determine the correlation between aPTT and anti-Xa values and to explore possible causes for non-correlating aPTT and anti-Xa, including CRP and AT plasma levels.

NCT ID: NCT05508958 Enrolling by invitation - Clinical trials for Loosening, Prosthesis

Cup Revisions Through Anterior or Posterolateral Approach: an RCT

Start date: September 8, 2022
Phase: N/A
Study type: Interventional

With increasing numbers of total hip arthroplasties performed each year, the incidence of problems related to loosening and wear of total hip arthroplasties is expected to also increase. While the anterior approach for primary total hip arthroplasty has demonstrated to result in a faster short-term recovery than the traditional lateral and posterior approach, this effect has not yet been investigated in revision surgery. Accelerating functional outcome may increase patient satisfaction and reduce healthcare costs. The primary objective is to assess whether isolated cup revision surgery through the anterior approach results in increased functional status and higher patient satisfaction than through the posterolateral approach. This is a prospective Randomized Controlled Trial (RCT) in which 68 patients will be included (34 per group). Patients will be evaluated preoperatively and 6 weeks, 3 months and 1 year postoperatively. The main endpoints are functional recovery as measured with the 30-sec Chair Stand Test (30s-CST), 40m Fast Paced Walking Test (40m FPWT) and the Stair Climb Test (SCT). Secondary endpoints are Modified Borg scale outcomes after the functional tests, Numeric Rating Scale (NRS) for pain (rest/movement), Oxford Hip Score (OHS), HOOS-PS, EQ-5D-5L, satisfaction, cup inclination and complications at 30 days and 90 days postoperatively.

NCT ID: NCT05508893 Terminated - Clinical trials for Coronary Artery Disease (CAD)

Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT)

SUSPECT
Start date: November 17, 2014
Phase: N/A
Study type: Interventional

SUSPECT is a prospective, single-center, cohort study of 250 military aircrew at the Center for Man in Aviation, Royal Netherlands Air Force. All asymptomatic aircrew (≥40 years) are asked to undergo a coronary CT scan on a voluntary basis, following the exercise electrocardiograms performed at their routine aeromedical examination. Coronary Artery Calcium score (CACS) and CCTA findings are reported.

NCT ID: NCT05508763 Recruiting - Clinical trials for Adverse Drug Reaction

Personalised Therapeutics @LUMC

PT@LUMC
Start date: December 1, 2022
Phase:
Study type: Observational

In PT@LUMC 2000 patients will be randomized between a PGx-guided dosing group and a standard of care group. The patients will be followed for one year in which they will be asked to report adverse drug reactions at one, three, six and twelve months.

NCT ID: NCT05508061 Completed - Type 1 Diabetes Clinical Trials

Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes

FAST 1
Start date: October 19, 2022
Phase: N/A
Study type: Interventional

The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1. In addition, safety parameters, pharmacodynamics and AP-related parameters will be acquired. This study is a multicenter, open-label, randomized, cross-over trial in 12 subjects. The subjects will be randomized to receive either Lyumjev or Humalog® for a 30-day study period and will then switch to the alternate insulin treatment after a wash-out period.

NCT ID: NCT05507983 Recruiting - Burns Clinical Trials

Tranexamic Acid During Excisional Burn Surgery

TRANEX
Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to access the efficacy of the drug tranexamic acid in reducing blood loss during burn excision surgery.

NCT ID: NCT05507775 Completed - Clinical trials for Non-Medullary Thyroid Carcinoma

Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma

DIGUP-TC
Start date: December 6, 2022
Phase: N/A
Study type: Interventional

Non-medullary thyroid carcinoma has a good prognosis in most patients. However, a small subset of patients nevertheless develop metastatic or locally advanced and unresectable disease which in some cases also becomes radioiodine refractory. In these patients treatment options are very limited. Earlier cell line and animal studies have shown that digoxin can reinduce radioiodine uptake in non-medullary thyroid cancer. This study serves as a proof of principle study to assess the possibility of digoxin to reinduce radioiodine uptake in adult humans with metastatic or locally advanced non-medullary radioiodine refractory thyroid carcinoma.